Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online October 1, 2007
Diabetes Care 31:44-46, 2008
DOI: 10.2337/dc07-0737
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-0737v1
31/1/44    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swan, K. L.
Right arrow Articles by Tamborlane, W. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swan, K. L.
Right arrow Articles by Tamborlane, W. V.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition/Psychosocial Research
Original Research

Effect of Puberty on the Pharmacodynamic and Pharmacokinetic Properties of Insulin Pump Therapy in Youth With Type 1 Diabetes

Karena L. Swan, MD1, Stuart A. Weinzimer, MD1, James D. Dziura, PHD2, Garry M. Steil, PHD3, Gayane R. Voskanyan, PHD3, Amy T. Steffen1, Melody L. Martin1 and William V. Tamborlane, MD1,2

1 Section of Pediatric Endocrinology, Yale University, New Haven, Connecticut
2 Center for Clinical Investigation, Yale University, New Haven, Connecticut
3 Medtronic MiniMed, Northridge, California

Address correspondence and reprint requests to Karen Swan, MD, Yale University, Section of Pediatric Endocrinology, 333 Cedar St., P.O. Box 208064, New Haven, CT 06520. E-mail: karena.swan@yale.edu

Abbreviations: GIR, glucose infusion rate

The first 20% of the full text of this article appears below.


   INTRODUCTION
 
Development of biosynthetic techniques for production of human insulin enabled the pharmaceutical industry to produce rapid-acting insulin analogs that are more rapidly absorbed following subcutaneous injection than regular insulin (1–5). These analogs may be especially useful in treating adolescents with type 1 diabetes who require large premeal bolus doses due to the peripheral insulin resistance of puberty (6). When used in large doses, the peak action of regular insulin is delayed (to 3–4 h) and the duration markedly prolonged (to 8 h or more) (7). The pharmacokinetic and pharmacodynamic properties of the rapid-acting insulin analogs have not been well studied in pediatric patients or when administered by continuous subcutaneous insulin infusion. This study was undertaken to examine the effect of puberty on the pharmacokinetics and -dynamics of aspart insulin in pump-treated patients.


   RESEARCH DESIGN AND METHODS—
 
A total of 21 healthy nonobese subjects with type 1 diabetes ranging in age from 8 to 17 years were studied. All were receiving continuous subcutaneous insulin infusion therapy and had A1C levels between 6.5 and 8.9%. The Yale Human Investigation Committee approved the study; written informed consent was obtained from the parents and assent from the subjects. Subjects were divided into two groups: prepubertal (Tanner stage I, n = 9) and pubertal (Tanner stages II–V, n = 12). The two groups did not differ significantly in A1C levels, duration of diabetes, and BMI percentiles. . . . [Full Text of this Article]


   RESULTS—
 

   CONCLUSIONS—
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.